Clinical Trial: Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824168) titled 'Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission' on Feb. 07.

Brief Summary: This clinical two-arm trial is designed to compare quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Study Start Date: March 25

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia Leukemia

Intervention: DRUG: Qu...